Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial The 3-year overall survival (OS) for advanced intrahepatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback